secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001213900-22-031985
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics shareholders elect three directors, ratify auditor, approve say-on-pay at 2022 annual meeting
--------------------------------------------------------------------------------

- Elected Luke Beshar, Roger Garceau, and Gregory Sargen as Class II directors to serve until 2025 annual meeting.
- Ratified Ernst & Young as independent registered public accounting firm for fiscal year ending Dec 31, 2022 with 8,385,650 votes for.
- Advisory vote approved compensation of named executive officers with 6,426,881 votes for, 126,276 against, 54,902 abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022031985/0001213900-22-031985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022031985/ea161338-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-031985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer